Nektar Therapeutics (NKTR) Receivables - Net (2010 - 2025)

Nektar Therapeutics' Receivables - Net history runs 16 years deep, the most recent figure standing at $400000.0 for Q4 2025.

• In Q4 2025, Receivables - Net changed N/A year-over-year to $400000.0; the TTM figure through Dec 2025 stood at $400000.0 (changed N/A YoY), while the FY2025 annual figure was $400000.0, changed N/A from the prior year.
• Receivables - Net was $400000.0 for Q4 2025 at Nektar Therapeutics, up from $200000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $30.2 million in Q1 2022 to a low of $200000.0 in Q3 2025.
• Historically, Receivables - Net has averaged $11.3 million across 5 years, with a median of $4.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net tumbled 90.09% in 2023, then climbed 20.77% in 2024.
• A 5-year view of Receivables - Net shows it stood at $22.5 million in 2021, then slumped by 73.41% to $6.0 million in 2022, then sank by 79.85% to $1.2 million in 2023, then dropped by 0.75% to $1.2 million in 2024, then slumped by 66.56% to $400000.0 in 2025.
• The last three Receivables - Net figures came in at $400000.0 (Q4 2025), $200000.0 (Q3 2025), and $1.2 million (Q2 2024), per Business Quant data.